Join

Compare · DXCM vs RSLS

DXCM vs RSLS

Side-by-side comparison of DexCom Inc. (DXCM) and ReShape Lifesciences Inc. (RSLS): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both DXCM and RSLS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
  • DXCM is the larger of the two at $23.76B, about 1249.7x RSLS ($19.0M).
  • Over the past year, DXCM is down 13.5% and RSLS is down 56.5% - DXCM leads by 43.0 points.
  • DXCM has hit the wire 4 times in the past 4 weeks while RSLS has been quiet.
  • DXCM has more recent analyst coverage (25 ratings vs 1 for RSLS).
PerformanceDXCM-11.93%RSLS-56.47%
2026-01-06+0.00%2026-04-24
MetricDXCMRSLS
Company
DexCom Inc.
ReShape Lifesciences Inc.
Price
$61.55-1.84%
$3.91+22.96%
Market cap
$23.76B
$19.0M
1M return
-7.89%
+37.92%
1Y return
-13.51%
-56.47%
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Exchange
NASDAQ
NASDAQ
IPO
2005
2016
News (4w)
4
0
Recent ratings
25
1
DXCM

DexCom Inc.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.

RSLS

ReShape Lifesciences Inc.

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in October 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.

Latest DXCM

Latest RSLS